# Dabigatran Versus Warfarin With NVAF Who Undergo PCI

> **NCT03536611** · PHASE4 · UNKNOWN · sponsor: **Shenyang Northern Hospital** · enrollment: 1120 (estimated)

## Conditions studied

- Atrial Fibrillation
- Coronary Artery Disease

## Interventions

- **DRUG:** dabigatran
- **DRUG:** warfarin

## Key facts

- **NCT ID:** NCT03536611
- **Lead sponsor:** Shenyang Northern Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-06-30
- **Target enrollment:** 1120 (ESTIMATED)
- **Last updated:** 2019-01-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03536611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03536611, "Dabigatran Versus Warfarin With NVAF Who Undergo PCI". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03536611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*